Ibrexafungerp for Invasive Aspergillosis
Patients battling invasive aspergillosis, a serious fungal infection, face unsatisfactory clinical outcomes with mortality rates up to 50% and long treatment durations. Additionally, current therapies are associated with drug-drug interactions, and there is an increasing emergence of A. fumigatus resistance.
We believe ibrexafungerp (formerly SCY-078) may provide improved therapeutic outcomes when added to existing standard of care (azoles). Ibrexafungerp's attributes, including strong activity again Aspergillus strains, high lung penetration, convenient oral formulation, and low risk of drug-drug interactions, make it a promising agent to treat invasive aspergillosis.